The biomarker core will provide a centralized resource for the rapid, high throughput quantification of transcripts and proteins. Transcripts will be quantified using quantitative PCR (Q-PCR). In addition the Biomarker Core will provide for genome-wide microarray analysis using an lllumina Beadstation. Quantification of protein levels in blood or tissue lysates will be done using a MesoScale Sector Imager or by reverse-phase protein array (RPPA) The biomarker core will serve to provide: 1) quantitative mRNA levels for known genes that are Involved In proliferation and implicated in cancer progression;2) identification of unique proteins, genes and expression profiles in cells or tissues after a molecular or pharmacologic manipulation;3) validation of the expression of genes that are initially identified in screening by microan-ays, 4) quantification of protein levels both as an independent validation technique and to determine the relationship between transcript levels and protein levels.
Specific Aims 1 -4 represent interactions between projects in the SPORE and the Biomarker Core.
Specific Aim 1 Metformin for the chemoprevention of endometrial cancer in obese, insulin resistant women. These studies will use both animal models of obesity and conduct a clinical trial using metformin and examine the impact on endometrial cancer. Biomarkers that will be measured include Ki-67, Cyclin A, sFRPI, sFRP4, survivin, EIG121, RALDH2, PR, ER, IGF-1 IGF-1 R. RPPA and microarrays will also be used in these studies.
Specific Aim 2. Sfrafegy for the Incorporation of Tissue S/omarkers in the Clinicai Management of Endometrial Cancer Patients. This project will assess the utility of a panel of 7 previously identified biomarkers in a large number of FFPE endometrial samples. This project will also use RPPA to help discover new biomarkers to augment the current biomarker panel.
Specific Aim 3 EphA2 Targeting in Uterine Carcinoma. These studies will evaluate the function of EphA2 in cancer and conduct a clinical trial of a novel immuno-conjugate that targets the EphA2 receptor. Q-PCR will assess the biomarkers listed above, markers of angiogenesis, and cell free nucleic acids. Pre-and post- biopsy endometrial will be assayed for the core biomarkers, markers of angiogenesis and EphA2 transcripts. Microarray studies will be conducted to identify both pathways and novel genes regulated by EphA2.
Specific Aim 4 Targeting the Pi3K Signaling Pathway in Endometrial Carcinoma. In these studies the Core will examine by RPPA approximately 550 tissue specimens for alteration in the expression and phosphorylation of members of the PISK signaling pathway.
Specific Aim 5 is a project within the Biomarker Core that will perform microarray analysis and QPCR validation on approximately 90 samples from patients with HNPCC at baseline and following 3 months of chemoprevention therapy with either oral contraceptives or depot medroxyprogesterone.
The biomarker core will provide a centralized resource for the rapid, high throughput quantification of transcripts and proteins for all components of the Uterine SPORE. Transcripts will be quantified using quantitative PCR (Q-PCR). In addition the Biomarker Core will provide for genome-wide microarray analysis using an lllumina Beadstation. Quantification of protein levels in blood or tissue lysates will be done using a MesoScale Sector Imager or by reverse-phase protein array.
|Du, Di; Ma, Wencai; Yates, Melinda S et al. (2018) Predicting high-risk endometrioid carcinomas using proteins. Oncotarget 9:19704-19715|
|Sun, Chaoyang; Yin, Jun; Fang, Yong et al. (2018) BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33:401-416.e8|
|Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15|
|Kim, Grace; Kurnit, Katherine C; Djordjevic, Bojana et al. (2018) Nuclear ?-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol 31:1553-1559|
|Yoo, Jung-Yoon; Kang, Hee-Bum; Broaddus, Russell R et al. (2018) MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT. BMC Cancer 18:605|
|Yuan, Ying; Lin, Ruitao; Li, Daniel et al. (2018) Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res 24:4921-4930|
|Yates, Melinda S; Coletta, Adriana M; Zhang, Qian et al. (2018) Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prev Res (Phila) 11:477-490|
|Yan, F; Thall, P F; Lu, K H et al. (2018) Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. Ann Oncol 29:694-699|
|Gao, Chao; Wang, Yingmei; Broaddus, Russell et al. (2018) Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget 9:5492-5508|
|Pan, Haitao; Liu, Suyu; Miao, Danmin et al. (2018) Sample size determination for mediation analysis of longitudinal data. BMC Med Res Methodol 18:32|
Showing the most recent 10 out of 578 publications